OCM
CLPT icon

Osbon Capital Management’s ClearPoint Neuro CLPT Stock Holding History

Osbon Capital Management’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.18K Hold
402
– – 0.01% 316
2026
Q1 		$3.66K Hold
402
– – ﹤0.01% 382
2025
Q4 		$5.51K Buy
+402
New +$7.45K 0.01% 274

Other funds holding CLPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
CFM
Compass Financial Management Tampa, Florida $829M AUM

Osbon Capital Management's CLPT Position: Q2 2026 in Review

Osbon Capital Management held its ClearPoint Neuro (CLPT) position steady in Q2 2026 at 402 shares worth $7.18K. The position accounts for 0.01% of the portfolio, ranked #316.

Osbon Capital Management first reported a position in CLPT in Q4 2025 and has held it in 3 quarters since. 128 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

  • Osbon Capital Management held 402 shares of ClearPoint Neuro worth $7.18K as of Q2 2026.
  • Osbon Capital Management left its ClearPoint Neuro share count unchanged in Q2 2026.
  • ClearPoint Neuro made up 0.01% of Osbon Capital Management's portfolio in Q2 2026, its #316 holding.
  • Osbon Capital Management first reported a position in ClearPoint Neuro in Q4 2025 and has held it in 3 quarters since.
  • 128 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on Osbon Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.